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Abstract Antithrombin (AT) is a glycoprotein that inac-
tivates the several physiological target enzymes of coagu-
lation system. The effect of purification strategies plays a
crucial role in getting maximum recovery of yield, purity
and biological activity of recombinant human antithrombin
(rhAT). In the present work, the task of purifying rhAT
from Saccharomyces cerevisiae BY4741 has been carried
out using two different approaches such as cross flow fil-
tration (CFF) system and chromatography methods. In the
first approach, the protein was concentrated and partially
purified through CFF to achieve maximum recovery yield
and purity of 87 and 94 %, respectively. In the second
approach, purification involved a single step chromatog-
raphy with various types of ion exchange and size exclu-
sion resins to analyze the maximum rhAT recovery yield
and purity. From the experimental results, it has been
observed that the size exclusion chromatography (SEC)
technique with Superose 12 matrix was suitable for the
purification of rhAT and achieved the maximum recovery
yield and purity of 51 and 97 %, respectively. Further, to
acquire a high recovery yield and purity of rhAT, the effect
of various chromatographic conditions such as mobile
phase, mobile phase pH, flow rate, sample volume and
sample concentration were also investigated. Under the
optimal chromatographic conditions, rhAT was signifi-
cantly recovered and purified in a single step with maxi-
mum recovery yield, purity and biological activity of 67,
99 % and 410 IU/L, respectively. Based on these
investigations, it was concluded that SEC with Superose 12
matrix was a more suitable and a potential method for the
purification of rhAT.
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Introduction
Antithrombin (AT) is a plasma glycoprotein (432 amino
acids) and a member of serine protease inhibitor (SERPIN)
family, which is an important physiological controller of
various clotting factors, including thrombin, factor IXa,
Xa, XIa, and XIIa (Rosenberg and Damus 1973; Franzen
et al. 1980). The inactivation of thrombin by AT under
normal physiological conditions is slow, but the rate of
complex formation increases in a high degree by heparin
cofactor activity (Machovich et al. 1976). AT has a ther-
apeutic significance for those who suffer from venous
thrombosis and pulmonary embolism with acquired or
inherited inadequacy of AT activity (Beresford and Owen
1990). In these situations, an adequate supply of pure AT is
essential.
Nevertheless, AT is available from human plasma
(Bu¨ntemeyer et al. 1994; Munzert et al. 1997), from the
view of product safety and possible virus infection (retro-
virus and hepatotropic viruses), AT production must be
only way through recombinant DNA (rDNA) technology
(Zettlmeissl et al. 1987). AT has been produced using
different expression systems like E. coli, Chinese hamster
ovary cells and Pichia pastoris, COS 1 monkey kidney
cells, BHK (baby hamster kidney) cells, Spodoptera fru-
giperda insect cells, and transgenic goat milk (Bock et al.
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1982; Wasley et al. 1987; Zettlmeissl et al. 1988, 1989;
Gillespie et al. 1991; Edmunds et al. 1998), but yeast-based
recombinant human antithrombin (rhAT) has been
demonstrated only by Broker et al. (1987).
To have the capacity to isolate a desired protein from a
mixture, the physicochemical properties of the target pro-
tein should be used. Till now, there is no single or simple
process to purify all kinds of proteins. On the other hand, if
the protein is intended for clinical use, it ought to be very
pure. But, as considered to be in economic view, purifi-
cation should be done in a single step.
The main objective of a purification process is not only
the exclusion of undesired contaminants, but also the
purification of the target protein (Roe 2001). Ion exchange
chromatography (IEC) is certainly the most commonly
used technique for the separation and purification of pro-
teins, polypeptides, nucleic acids, poly nucleotides, and
other bio molecules. The explanations behind the accom-
plishment of IEC are its determining power, broad rele-
vance, high capacity, and the effortlessness of the system
(Bonnerjea et al. 1986). Size exclusion chromatography
(SEC) is another purification process, in which components
are filtered according to their size, and in some times
molecular mass. It is frequently used to purify the larger or
macro molecules such as proteins and industrial polymers
(Paul-Dauphin et al. 2007).
In the present study, purification of rhAT from
Sacharomyces cerevisiae BY4741 has been carried out
using two different approaches such as cross flow filtration
(CFF) and chromatography methods to achieve high
recovery yields and purity. In addition, the effect of various
physicochemical parameters such as mobile phase, mobile
phase pH, flow rate, sample volume and sample concen-
tration on rhAT purification were also investigated.
Methods
Chemicals and instrumentation
Tris or Tris aminomethane and 2-mercaptoetahnol were
procured from Merck Millipore (USA). Fraction V or
Bovine serum albumin (BSA) and phenylmethanesul-
fonylfluoride (PMSF) were obtained from Sigma (Ger-
many). rhAT reference standard was purchased from
NIBSC, UK. SDS-PAGE Mini-PROTEAN three apparatus
was procured from Bio-Rad Laboratories Inc., (USA).
Recombinant human AT was produced in a Minifors fer-
mentor (Infors HT, Switzerland). The Fast protein liquid
chromatography (FPLC) AKTA Prime Plus system, resins
(stationary phase), bioprocess glass column (BPG XK16/
20) for purification, cross flow filtration (CFF) system and
the hollow fiber membrane cartridge (30 kDa) were
purchased from GE Healthcare Life sciences (Uppsala,
Sweden). The chromatographic data were recorded and
analyzed by Prime View EvaluationTM software version 5.
31. Reversed phase high pressure liquid chromatography
(RP-HPLC) equipped with UV/Vis (SPD 20A Prominence)
detector was acquired from Shimadzu Corp. (Kyoto,
Japan). The Jupiter 300 A˚ C4 LC column (250 9 4.6 mm)
obtained from Phenomenex (USA).
Production of rhAT
Large scale production of rhAT in S. cerevisiae BY4741
was performed in a fed-batch cultivation mode with a
media volume of 3 L in Minifors HT bioreactor (Infors HT,
Switzerland). The fermentation process was carried out in
the following conditions: temperature 30 C, pH 7.1, 40 %
dissolved oxygen (DO). The foaming was controlled with a
silicon antifoaming agent. The culture was induced with
galactose (2 %) at an OD600 nm of 0.9 (dry cell
weight = 11 g/L) of the fermented culture (Kim et al.
2003; El-Sayed et al. 1990).
Cell harvesting and lysis
The fermented broth was harvested and the pellet was
collected by centrifugation (Sorvall ST 16 R, Thermo
scientific, Pittsburgh, PA, USA) at 4 C and 40,0009g for
15 min. The pellet weight was calculated as dry cell weight
(DCW, g/L). The cells were washed with wash buffer
containing 0.05 M EDTA (pH 8.0) and 0.01 M Tris-HCl
(pH 7.6). The cells were lysed by sonication (20 kHz, for
2–4 s time intervals) using lysis buffer containing 0.01 M
Tris-HCl (pH 7.6), 1 % DMSO, 50 mM NaCl,1 mM
EDTA, 0.5 % sucrose and 1 mM phenylmethylsulfonyl
fluoride (PMSF).
Concentration of rhAT protein solution
After cell lysis, the lysate was concentrated and simulta-
neously clarified using CFF system with a loading volume
of 500 mL. The rhAT protein was filtered through 30 kDa
molecular weight cutoff hollow fiber membrane cartridge
with nominal flow path length of 30 cm with 650 cm2 of
cross-sectional area. The maximum flux (flow) rate from
the membrane was allowed at 10 mL/min. The filtration
was accomplished using a stable pump speed at 300 rpm.
The concentration intensity of the rhAT is distinguished by
a concentration factor (fC) and retention factor (Rf), and
these are calculated from the following formula.
fc ¼ VF=VC ð1Þ
where VF = feed volume and VC = final cross (retentate)
volume. The retention factor is also a significant parameter
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for the desired product characterization, and it is described
as, the division of components between permeate and
retentate.
Rf ¼ ððCFÞ2  CpÞ=CF ð2Þ
where, CF = feed concentration and Cp = permeate con-
centration (Vemula et al. 2015).
Purification of rhAT
Two different column chromatography techniques with
different resins were selected to analyze the effect of sta-
tionary phase on rhAT purification. The principle of IEC
with Q-Sepharose and Capto Q and CM Sepharose were
applied to evaluate the effect of stationary phase on rhAT
purification (Lutkemeyer et al. 1993). Simultaneously, the
principles of SEC with three different resins (Sephacryl
S200, Sephadex G-100 and Superose 12) were also applied
to analyze the effect of stationary phase on yield and purity
of rhAT (Sˇtulı´k et al. 2003). A 25 mL of each stationary
phase with 20 % ethanol solvent was filled through 0.2
Mpa pressure in the bioprocess glass (BPG) column (BPG
XK16/20). The column was primarily washed with 100 mL
of 0.5 M sodium chloride solution with a flow rate of
3.0 mL/min. The column is washed with 100 mL water to
remove the salts and other contaminants during equilibra-
tion with the mobile phase. For every individual experi-
ment, 2 mL of rhAT protein was loaded and the column
pressure was maintained at 0.1–0.2 Mpa during the
purification process. 50 mL of salt linear gradient program
was run for the purifications from 20 to 100 % sodium
chloride solution at a constant flow rate of 1.0 mL/min.
Protein elution profiles were detected at 280 nm. All the
purification experiments have been performed at 22 C.
Analytical procedures
The purity of the rhAT was assessed by reverse phase
liquid chromatography (RP-HPLC) (Vanz et al. 2008) and
SDS-PAGE (15 % w/v acrylamide (Faraji et al. 2010). The
qualitative analysis of the rhAT was analyzed through RP-
HPLC. HPLC system (Shimadzu, Kyoto, Japan) was
equipped with LC Prominence SPD 20A UV–Visible
detector and LC 20 AT binary pumps. The rhenodyne type
of injector port was used to inject the samples. The rhAT
analysis was carried out at the following conditions: flow
rate 1.0 mL/min, wavelength 280 nm, pressure 80 kgf and
controlled temperature 40 C. The Jupiter 300 A˚ C4 5 l
column (250 9 4.6 mm) (Phenomenex, USA) was used to
analyze the samples. The mobile phase A consisted of
water: acetonitrile (87.5:12.5 v/v) and mobile phase B
consisted of water: acetonitrile (30:70 v/v). Mobile phase A
and B consisted of TFA (ion pairing agent) with the
concentration of 0.1 and 0.08 %, respectively. The rhAT
was eluted using linear gradient mode with % B to 90 % B
in 20 min and 90 % B to 5 % B in 40 min. The purified
rhAT concentration was calculated by Bradford assay using
BSA as a standard (Tesio et al. 2011).
On the other hand, Purified rhAT III and control was
loaded onto 15 % SDS-PAGE and transferred to
polyvinylidene difluoride membrane and western blot
analysis was performed using polyclonal antibody gener-
ated from rabbits and Horseradish peroxidase conjugated
goat IgG antibody (Bio-Rad Inc, USA) (Kuwae et al.
2005). The biological potency of the purified rhAT III was
measured as heparin cofactor (HC) activity with a com-
mercial assay kit that uses the thrombin-specific chro-
mogenic substrate S-2238 (TESTZYM ATIII kit, Daiichi
Pure Chemical, Tokyo).
Results and discussion
Preparation of concentrated solution and fractional
purification of rhAT
Cell lysate was concentrated and partially purified by cross
flow filtration system using 30 kDa catridge. The rhAT
filtration performance is shown in Fig. 1. From the
experimental results, the change in rhAT concentrations
(0.4, 1.1, 2.6, 3.9, 5.7, 6.8 and 7.2 mg/mL) with change in
flux (21, 17.5, 13.6, 10.8, 6.7, 3.5 and 2.9) was observed
(Fig. 1) at progressive time intervals (0, 30, 60, 90, 120,
150 and 180 min). It can be clearly observed that a note-

































Fig. 1 Clarification and concentration of rhAT. Effect of filtration
during ultra filtration with hollow fiber cartridge, rhAT concentration
was shown increasing with respective to the decrease in flux as a
function of time; filled square represents rhAT concentration; filled
diamond represents flux
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with decrease in flux as a function of time. At a specific
time period (180 min), no significant change was observed
and a high 7.2 mg/mL of rhAT concentration was obtained
with a constant flux of 2.9 mL/min. This effect may be due
to the clogging of pores by formation of foam on the sur-
roundings of membrane that constrained the filtration of
solution from the membrane. The filtration was ended after
recovering 40 mL retentate with a concentration factor of
12.5 and retention factor of 0.87. The rhAT recovery yield
and purity after the filtration step was about 87 and 94 %,
respectively. Various recombinant proteins such as
recombinant human granulocyte stimulating factor (rhG-
CSF) and monoclonal antibodies have been successfully
concentrated with cross flow filtration system and it was
achieved with[95 % purity (Vemula et al. 2015; Liu et al.
2010).
Effect of chromatographic resin on rhAT
purification
Optimization should evaluate a number of physicochemical
parameters including stationary and mobile phase for
effective protein purification. Therefore, the studies have
been conducted on rhAT purification to analyze the influ-
ence of ion exchange and size exclusion chromatographic
resins. The recovery yield and purity of rhAT for both ion
exchange and size exclusion chromatography with differ-
ent resins were shown in Table 1. From the results, it can
be seen that among various resins selected in both ion
exchange and size exclusion chromatography, size exclu-
sion chromatography with Superose 12 showed maximum
recovery yield and purity of 51 and 97 %, respectively. The
lower yields with ion exchange could be attributed to low
permeability and capacities of resins for larger proteins
such as antithrombin. Additionally, the hydrophobic char-
acter of the ion exchange resin will denature the proteins
(Janson 2012). Therefore, further experiments were carried
out with Superose 12. The above experimental results
obtained in the present work were significantly higher than
the work reported by Mak et al. (1996).The effect of var-
ious chromatographic resins on recombinant protein (rhG-
CSF) purification was also successfully studied by other
researchers (Wang et al. 2006).
Effect of Mobile phase on rhAT purification
The choice of mobile phase plays a critical role in the
purification of proteins because they ought to be adapted to
the buffer atmosphere during the elution. In the present
work, a study has been performed on four different mobile
phases (tris, acetate, phosphate and sulfate) with pH 7.2
using size exclusion chromatography with Superose 12.
The recovery yield and purity of rhAT with four different
mobile phase buffers were shown in Table 2. From the
experimental results, recovery yields (50, 52, 54 and 51 %)
and purities (97, 98, 98 and 97 %) of rhAT were obtained
with respective mobile phase buffers such as tris, acetate,
phosphate and sulfate buffers. From the above result
analysis, it was concluded that phosphate buffer has
achieved a high recovery yield (54 %) with 98 % purity.
The lowest recovery yield (50 %) was achieved with Tris
buffer with 97 % purity. However, acetate and sulfate are
next to the phosphate with recovery yields of 52 and 51 %,
respectively. The results attained in the present work were
higher than the previously reported work (Mochizuki et al.
2001).The effect of mobile phase on recombinant protein
(rhG-CSF) purification was also successfully studied by
other researchers (Vemula et al. 2015).
Effect of mobile phase pH on rhAT purification
Purification of proteins is pH dependent, which can defi-
nitely affect the recovery yield and purity (Burgess et al.
1987). In the present work, a study has been carried out on
phosphate buffer with different pH values ranging from 6.5
to 9 to estimate their effect on recovery yield and purity of
rhAT. The recovery yield and purity of rhAT at various
phosphate buffer pH values were shown in Fig. 2. From the
experimental results, recovery yields (48, 50, 51, 53, 55
and 52 %) and purities (97, 97, 98, 98, 98 and 98 %) of
rhAT were obtained with respective mobile phase pH such
as 6.5, 7, 7.5, 8, 8.5 and 9. It has been clearly observed that
the maximum recovery yield (55 %) and purity (98 %) of
rhAT was observed with buffer at pH 8.5. The lowest
recovery yield (48 %) and purity (97 %) of rhAT was
observed with buffer at pH 6.5. Even though the purity was
high (98 %) at pH 7.5,8 and 9, low recovery yields (51, 53
Table 1 Effect of stationary phase on rhAT purification, the maximum yield (51 %) and purity (97 %) of rhAT was shown with Superose 12.
The results represent mean values with standard deviation (SD) of three repeated (triplicates) experiments
Ion exchange resin Size exclusion resin
Q-Sephrose Capto Q CM Sepharose FF Sephacryl S200 Sephadex G-100 Superose 12
Recovery yield (%) 43 ± 1.2 46 ± 1.2 48 ± 1.1 49 ± 1.2 48 ± 1.2 51 ± 1.1
Purity (%) 96 96 97 97 97 97
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and 52 %) were observed when compared to pH 8.5.The
mobile phase pH on recombinant protein purification was
also successfully analyzed by previously reported work
(Vemula et al. 2015).
Effect of flow rate on rhAT purification
Flow rate should be considered as one of the most signif-
icant parameters during protein purification, because in
size-based separations, it may influence the protein struc-
ture, biological activity and recovery yield. In the present
work, a study has been conducted with different flow rates
of 0.5, 1.0, 1.5 and 2.0 mL/min to show the impact of flow
rate on rhAT purification. The recovery yield and purity of
rhAT at different flow rates were shown in Fig. 3. From the
experimental results, recovery yields (59, 66, 61 and 57 %)
and purities (98, 99, 98 and 98 %) of rhAT were obtained
with respective flow rates such as 0.5, 1, 1.5 and 2 mL/min
flow rate. It can be clearly seen that the high recovery yield
(66 %) and purity (99 %) of rhAT was obtained with
1 mL/min flow rate. Although using lower sample flow
rates results in longer run times, the increased resolution
gives greater confidence and optimum column efficiency
(Oliva et al. 2001). The low recovery yield (57 %) was
observed with 2 ml/min, due to high acceleration, which
increased the chance of escaping and decreased the passage
of the sample from the resin resulting in low recovery
yields. Though the purity of rhAT is similar at 0.5, 1.5 and
2 flow rates, variations in recovery yields (59, 61 and
57 %) were observed. Hence further experiments were
carried out with 1.0 mL/min flow rate. The results obtained
in this study were very close to the previously reported
work (Wang et al. 2014)
Effect of sample volume on rhAT purification
Sample injection volume can influence the protein purifi-
cation and affects mostly on recovery yields. Therefore, in
the present study, several experiments were carried out on
rhAT purification with different sample volumes such as 1,
2, 3, 4 and 5 mL. The recovery yield and purity profiles of
rhAT with varying sample volumes were shown in Fig. 4.
From the experimental results, recovery yields (55, 60, 57,
56 and 58 %) and purities (98, 98, 98, 98 and 98 %) of
rhAT were obtained with respective sample volumes such
as 1, 2, 3, 4 and 5 mL. From result analysis, it was con-
cluded that the maximum recovery yield (60 %) and purity
(98 %) with the sample volume of 2 mL were observed.
This is attributed to the suitable volume of the sample that
enters through the resin and increases the passage of
desired protein molecules. The lowest recovery yields of 55
and 56 % were achieved with 1 and 4 mL volumes,
Table 2 Effect of mobile phase on rhAT purification. The maximum
recovery yield (54 %) and purity (98 %) of rhAT was shown with
Superose 12 matrix. The results represent mean values with standard
deviation (SD) of three repeated (triplicates) experiments
Mobile phase buffer Recovery yield (%) Purity (%)
Tris 50 ± 1.1 97
Acetate 52 ± 1.2 98
Phosphate 54 ± 1.1 98























Fig. 2 Effect of mobile pH on rhAT purification, the maximum yield
(55 %) and purity (98 %) of rhAT was shown with pH 8.5. Filled
diamond represents recovery yield; Filled square represents purity.
The results represent mean values with standard deviation (SD) of























Fig. 3 Effect of flow rate on rhAT purification. The maximum yield
(66 %) and purity (99 %) of rhAT was shown with 1 mL/min flow
rate. Filled diamond represents recovery yield; filled square repre-
sents purity. The results represent mean values with standard
deviation (SD) of two repeated (duplicates) experiments
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respectively. This is due to broadening of sample zone by
increasing the sample volume and decreased the passage of
the sample through the resin. Therefore, further studies
were continued with 2 mL sample volume.
Effect of protein concentration on rhAT purification
Sample concentration may also influence the chromato-
graphic resolution and sensitivity (Hong et al. 2012). In the
present work, a study has been conducted on different
protein concentrations ranging from 1 to 4 mg/ml with
Superose 12 matrix to analyze the protein concentration
effect on recovery yield and purity of rhAT. Figure 5
shows the recovery and purity of rhAT under various
sample concentrations. From the experimental results,
recovery yields (63, 67, 61 and 60 %) and purities (98, 99,
99 and 98 %) of rhAT were obtained with respective
protein concentrations such as 1, 2, 3 and 4 mg/mL. From
the above result analysis, it can be clearly seen that the high
recovery yield (67 %) and purity (98 %) of rhAT were
achieved with protein concentration of 2 mg/mL. Even
though a high purity (98 %) of rhAT was observed with
protein concentration of 3 mg/mL, recorded low recovery
yields of 61 %. From this study, it was concluded that the
loss of recovery yields could be observed with increase in
protein concentration due to non-binding interactions of
protein with resin.
Optimal conditions for rhAT purification
Based on previous experiments, the optimal chromato-
graphic conditions were preferred for rhAT purification:























Fig. 4 Effect of sample volume on rhAT purification. The maximum
recovery yield (60 %) and purity (98 %) of rhAT was achieved with
2 mL sample volume. Filled diamond represents recovery yield; filled
square represents purity. The results represent mean values with
























Fig. 5 Effect of protein concentration on rhAT purification. The
maximum yield (67 %) and purity (99 %) of rhAT was shown with
2 mg/mL concentration. Filled diamond represents recovery yield;
filled square represents purity. The results represent mean values with










0.0 5.0 10.0 15.0 20.0 25.0 min
Fig. 6 FPLC chromatogram of rhAT eluted from the SEC column.
The maximum yield (67 %) and purity (99 %) of rhAT was shown
under optimum conditions: stationary phase: Superose 12; phosphate
buffer with pH: 8.5; flow rate: 1 mL/min; sample volume: 2 mL and
sample concentration: 2 mg/mL
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1 mL/min, sample volume 2 mL and sample concentration
is 2 mg/mL. Figure 6 shows the FPLC chromatogram of
rhAT eluted under the aforesaid optimized conditions. It
can be observed that the single major peak was observed
and indicates the monomeric form of rhAT. The major
peak appeared with high resolution at a retention volume of
13.3 mL indicating the active fraction of rhAT. The whole
chromatographic process was carried out in 25 min. The
obtained recovery yield and purity of rhAT under optimum
conditions were 67 % and C98 %. The above experimental
results obtained in the present work were significantly
higher than the previously reported work (Bu¨ntemeyer
et al. 1994; Mochizuki et al. 2001) and obtained results
were also very close to the earlier reported work (Wang
et al. 2014). Figure 7 shows the RP-HPLC chromatogram
eluted from the SEC column under optimized conditions. It
can be seen that the purity of rhAT was shown to be 98 as
similar with retention time (22.756 min) of standard rhAT.
The purity of rhAT was also assessed through SDS-
PAGE and western blotting. SDS–PAGE analysis of rhAT
III was shown in Fig. 8. A single target rhAT III band
confirms the molecular mass of 58 kDa, which is similar to
the control (standard rhAT III). On the other hand, gel was
transferred to PVDF membrane and the transformation was
immuno detected with rhAT III antibodies and a single
rhAT III band was shown in Fig. 9, which is analogous to
the reference standard. Finally, biological activity of
purified rhAT was found to be 410 IU/L measured as
heparin cofactor (HC) activity.
Conclusions
In summary, SEC is found to be an effective technique for
rhAT purification and showed a maximum recovery yield
(51 %) and purity (97 %) when compared to the IEC
Fig. 7 RP-HPLC analysis of
rhAT, the purity of the rhAT
was shown to be C98 %
Fig. 8 SDS-PAGE analysis of rhAT: Lane M marker; Lane 2 purified
rhAT; Lane 3 reference standard. A single target band was observed
with molecular weight of approximately 58KDa, which is similar to
the reference standard
Fig. 9 Western blot analysis of
rhAT. Both purified and refer-
ence standard rhAT bands were
characterized using polyclonal
antibody and HRPO conjugated
goat IgG antibodies against
antithrombin
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recovery yield (48 %) and purity (97 %). Further investi-
gations on physicochemical chromatographic conditions
such as mobile phase, mobile phase pH, flow rate, sample
volume and sample concentration were also proved their
influence on recovery yield and purity. Under the opti-
mized conditions, the maximum recovery yield, purity and
biological activity of rhAT was found to be 67, 99 % and
410 IU/L, respectively. The purity was evaluated through
various analytical techniques such as RP-HPLC, SDS-
PAGE and western blotting.
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